Ricardo Fernandes awarded a Cancer Research UK Immunology Project Award
8 March 2024
CAMS-Oxford Institute Principal Investigator, Ricardo Fernandes, has been awarded a competitive grant from Cancer Research UK to study anti-tumour T cell responses.
New study suggests antiviral treatment course is not long enough to treat COVID-19 in at risk patients
26 February 2024
New research published in Nature Communications suggests that the currently recommended five-day course of molnupiravir, an antiviral treatment, may not be long enough to treat COVID-19.
Study finds high number of persistent COVID-19 infections in the general population
22 February 2024
A new study led by the Big Data Institute at NDM has found persistent COVID-19 infections are surprisingly common, with around one to three in every 100 infections lasting a month or longer.
Rising antimicrobial resistance in enteric fever across 75 countries
16 February 2024
Recent findings by the Global Research on Antimicrobial Resistance Project at NDM's Centre for Tropical Medicine and Global Health revealed the resistance patterns for a priority pathogen--also known as typhoid fever--with high mortality and morbidity in resource-constrained settings.
R21 malaria vaccine phase III trial confirms high efficacy and safety
5 February 2024
The phase III trial data results of the R21/Matrix-M vaccine, developed by the Jenner Institute and the Serum Institute of India have confirmed high efficacy and supported regulatory approvals and licensure in several African countries.
World Cancer Day 2024: Highlighting cancer research at the MRC WIMM
4 February 2024
This World Cancer Day, we heard from four Group Leaders at the MRC Weatherall Institute of Molecular Medicine about their work and how their groups are helping in the fight against cancer.
AI-based method provides insights for predicting colorectal cancer outcomes
2 February 2024
The largest multiparameter immunoprofiling study in cancer to date has suggested an underappreciated role of a subset of immune cells in determining the risk of bowel cancer relapse after surgery.
Study uncovers how the Hepatitis B virus adapts
30 January 2024
A new hepatitis B study reveals how viruses adapt to low-oxygen environments, such as those found deep within the liver, opening up possible new therapeutic targets for liver pathogens. NDM researchers have identified hypoxia-inducible factors (HIFs) playing an important role in the regulation of editing of viral RNAs in low oxygen conditions.
UK minister meets with Oxford pandemic researchers
29 January 2024
Researchers at the Jenner Institute, the Oxford Vaccine Group and the Pandemic Sciences Institute hosted the Rt Hon Andrew Mitchell MP, Minister for Development and Africa, to the laboratories and clinics of several of its vaccine development groups.
Research into ancient DNA sheds new light on cause of Multiple Sclerosis and other neurodegenerative diseases
11 January 2024
Research led by scientists at the Universities of Oxford, Cambridge, Copenhagen, Bristol and California (Berkeley) reveals the evolutionary origins of multiple sclerosis (MS). This new insight into the genetic architecture of this disease changes scientists’ view of its causes and has implications for its treatment, as well as paving the way for further investigations into other diseases.
MORU leads study testing a single pill for drug-resistant malaria in Africa and Asia
15 December 2023
To boost the fight against drug-resistant malaria parasites now emerging in Africa, researchers at the Mahidol Oxford Tropical Medicine Research Unit will study the safety and efficacy of a fixed-dose combination (FDC) containing three antimalarial drugs currently given to patients separately in a triple artemisinin-based combination therapy (TACT) cocktail.
VALIDATE network receives Medical Research Council grant
13 December 2023
An international network of researchers, led by NDM’s Professor Helen McShane and Professor Samantha Sampson from Stellenbosch University, has recently been awarded a new UK Medical Research Council (MRC) grant to continue the network activities until 2027.
Oxford Vaccine Group, Department of Paediatrics, University of Oxford receives £7.8 million in research funding to fight pandemic and epidemic threats
13 December 2023
Oxford Vaccine Group (OVG), which led the rapid clinical development of the Oxford vaccine in COVID-19 in the pandemic, has been awarded a total of £7,788,783 by UK Aid for research into the prevention of five dangerous diseases with epidemic or pandemic potential. The awards will fund research into vaccines against: Chikungunya and mayaro virus, Marburg virus, Plague (Yersinia pestis), Q Fever (Coxiella burneti) and Sudan Ebolavirus.
£4.3m boost for Oxford-Glasgow spinout tackling antimicrobial resistance
15 November 2023
Glox Therapeutics, a company pioneering the development of precision antibiotics to combat antimicrobial resistance, has raised £4.3M in early-stage funding to develop effective targeted therapeutics against antibiotic-resistant gram-negative bacteria.
Single cell spatial analysis provides new insight into immune-pathology in Covid-19 lungs
9 November 2023
A Nature Communications study led by Professor Ling-Pei Ho’s group in the MRC Translational Immune Discovery Unit (TIDU) provides new insights into how immune cells interact in the lungs of patients with severe COVID-19.
New discovery furthers our understanding of how critical immune cells are controlled during an infection
9 November 2023
A recent publication from Research from the Gerard Lab in Kennedy Institute of Rheumatology looks at how a specific protein, called IFNγ, can coordinate CD8+ T cell responses during a flu infection.
Oxford launches new vaccine trial to enhance design of flu & COVID-19 vaccines
26 October 2023
This study will test the responses of cells in lymph nodes before and after immunisation with flu and COVID-19 vaccines and compare reactions in older and younger adults
Understanding how lipids influence immune responses
3 October 2023
In a study, recently published in the Cell, an international team of scientists, including CAMS Oxford Institute (COI) group leaders Professor Graham Ogg and Dr Yi-Ling Chen, has developed a method for simultaneously detecting thousands of lipid molecules that are displayed to T cells in the human immune system.